Propofol Composition for Inhibiting Dengue Virus Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dengue virus infection are inadequate, particularly in addressing severe forms like dengue hemorrhagic fever/dengue shock syndrome, with a high mortality rate and limited pharmacological effects on viral infection beyond general anesthetics.
Innovation Solution
Administering a pharmaceutical composition containing 2,6-diisopropylphenol, also known as propofol, to inhibit dengue virus release and block viral protein expression, thereby reducing symptoms and viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for dengue virus infection, then general symptom management is provided, but antiviral efficacy is insufficient and mortality rate remains high
Solution Approach 1:
The patent applies parameter changes by utilizing propofol at specific concentrations (0.1-10 μg/mL) to achieve antiviral effects against dengue virus. The compound's pharmacological parameters are optimized to inhibit viral replication while maintaining safety, transforming propofol from a purely anesthetic agent to an antiviral medication with controlled dosage parameters.
2Reliability
If propofol is administered to inhibit dengue virus release and block protein expression, then antiviral effectiveness is improved, but drug availability and accessibility may be limited
Solution Approach 1:
The patent leverages the multi-functionality of propofol, which is already an approved anesthetic agent with established manufacturing processes and regulatory approval. By repurposing this existing drug for antiviral treatment, the invention avoids the need for entirely new drug development, thereby improving availability while maintaining high antiviral effectiveness.
3Productivity
If propofol is used to treat dengue virus infection, then viral replication is inhibited and symptoms are reduced, but the mechanism of action is not fully understood compared to conventional antivirals
Solution Approach 1:
The patent incorporates feedback mechanisms by monitoring viral replication levels and adjusting propofol dosage accordingly. The treatment protocol includes assessing clinical response and viral load to optimize dosing, creating a feedback loop that enhances antiviral productivity while gradually building understanding of the drug's mechanisms through clinical observation and data collection.
Data Source
AI summary
The present disclosure provides a method for ameliorating and/or treating dengue virus infection or symptoms of dengue virus infection comprising administrating a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises an effective amount of 2,6-diisopropylphenol and optionally a pharmaceutically acceptable carrier.